Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166423 | 0.83 | POLB (0.36) | RPS6KA5TYRO3DYRK1B | |
| SCHEMBL24053348 | 0.83 | POLB (0.36) | RPS6KA5TYRO3DYRK1B | |
| SCHEMBL28987737 | 0.75 | TYRO3 (0.33) | TYRO3DYRK1BKDM4E | |
| SCHEMBL27967733 | 0.73 | DPP4 (0.37) | RPS6KA5 | |
| SCHEMBL1671095 | 0.72 | GABRA1 (0.34) | — | |
| SCHEMBL31589333 | 0.71 | LMNA (0.41) | — | |
| SCHEMBL29174727 | 0.70 | RPS6KA5 (0.43) | RPS6KA5BTKTYRO3DYRK1BKDM4E | |
| SCHEMBL30725466 | 0.70 | RPS6KA5 (0.43) | RPS6KA5BTKTYRO3DYRK1BKDM4E | |
| SCHEMBL2060450 | 0.70 | BCL6 (0.39) | — | |
| SCHEMBL16665702 | 0.69 | RPS6KA5 (0.42) | RPS6KA5BTKTYRO3DYRK1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105849099-B | Polycyclic inhibitors of cyclin dependent kinase 7(CDK7) | 达纳-法伯癌症研究所股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015058163-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | RPS6KA5 765/4885BTK 3043/4885TYRO3 3073/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | RPS6KA5 312/4885BTK 3238/4885TYRO3 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.